Chardan Capital Keeps Their Buy Rating on RegenXBio (RGNX)


In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on RegenXBio (RGNX), with a price target of $127.50. The company’s shares closed on Friday at $70.60.

Amusa wrote:

“We suspect the Abeona agreement will begin a trend of REGENXBIO capturing economics on the considerable number of products utilizing REGENXBIO’s vectors without an explicit license. In our 10 July research, we wrote “on REGENXBIO science as the leading driver of the emergence of AAV-based gene therapy,” and listed products utilizing REGENXBIO’s vectors. In particular, we noted Sarepta Therapeutics’ (unrated) GT candidate for Duchenne muscular dystrophy (DMD) uses an AAVrh74 vector that to us is likely within the scope of the IP for vectors in REGENXBIO’s NAV Technology Platform. We now note Sarepta recently expanded its GT pipeline, through a partnership with Myonexus Therapeutics (private), to include assets that also use AAVrh74.”

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 20.3% and a 46.8% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catalyst Biosciences Inc, and Adverum Biotechnologies.

RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $105.25, which is a 49.1% upside from current levels. In a report issued on October 29, Raymond James also maintained a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

RegenXBio’s market cap is currently $2.28B and has a P/E ratio of 32.69. The company has a Price to Book ratio of 7.18.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts